1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Multi-step timeline: LOI (required) due April 16, 2024; LOI screening results notified by April 25, 2024; Full application due May 27, 2024 by 5:00 PM local time. Only invited applicants who pass LOI screening may submit a full application. Deadline has passed.
Development and Application of Ophthalmic Imaging Technologies to Advance Our Understanding of Systemic Diseases (OT2) is sponsored by NIH Common Fund. Supports the development and application of ophthalmic imaging technologies to advance understanding of systemic diseases through the Oculomics Initiative.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-RM-24-007: Notice Announcing Publication of Development and Application of Ophthalmic Imaging Technologies to Advance Our Understanding of Systemic Diseases (OT2) Research Opportunity Announcement Notice Announcing Publication of Development and Application of Ophthalmic Imaging Technologies to Advance Our Understanding of Systemic Diseases (OT2) Research Opportunity Announcement Office of Strategic Coordination ( Common Fund ) Letter of Intent (LOI) Due Date (Required): April 16, 2024, by 5:00 PM local time of applicant.
LOIs are required. Only invited applicants meeting LOI screening criteria will be eligible to submit a full application. Notification of LOI Screening results: provided to applicants by April 25, 2024.
Application Due Date : May 27, 2024, by 5:00 PM local time of applicant organization. Late applications to this ROA will not be accepted. This initiative is funded through the NIH Common Fund , which supports cross-cutting programs that are expected to have an exceptionally high impact.
All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems or to seize new opportunities that offer the potential for rapid progress. This initiative is part of the Venture Program , a new effort within the Common Fund to support novel, short-term, bold initiatives that have the potential for significant impact in biomedical and behavioral research.
Venture initiatives are innovative and nimble, introducing additional flexibility for the Common Fund to tackle a wider variety of research topics. Venture initiatives embrace scientific risk and have strong potential to accelerate science rapidly. These short-term initiatives will be supported for a maximum of 3 years and will include clearly defined goals and milestones to facilitate rigorous measurement of research progress.
Each Venture initiative is expected to produce specific deliverables, which can be new knowledge, methods, technologies, or devices.
Research Opportunity Announcement OTA-24-006 is issued by the NIH Common Fund Venture Program Oculomics Initiative for the development and application of novel, noninvasive ocular imaging technologies and machine learning algorithms to identify highly sensitive and specific biomarkers for diseases that affect the entire body.
Oculomics can have a significant impact on early detection of diseases before the onset of symptoms, and can help clinicians with early disease intervention, risk assessment, tracking disease progression, and supportive therapeutics.
The initiative is not intended to support expansion of previous or ongoing efforts that currently utilize Optical Coherence Tomography (OCT), OCT-Angiography (OCTA), or color fundus photography for detection of systemic diseases. However, applications proposing new efforts that utilize OCT, OCTA, or fundus photography and can demonstrate a novel approach and/or clear technological advancement over existing technology may apply.
Applicants must address at least one systemic disease in neurology, cardiovascular, or metabolic diseases/disorders. Applications that focus on more than one systemic disease/disorder, more than one area of disease/disorder or utilize multiple imaging modalities are encouraged. The initiative encourages but does not require the development of machine learning algorithms to support the application of novel imaging technologies.
By the end of the three-year period of performance, developed technologies should be demonstrated in appropriate animal models of disease or human patients. Products from this initiative are expected to be matured for future clinical validation. An Informational Webinar will be held for potential applicants April 4, 2024.
Registration information for the Webinar and additional information on the ROA will be posted on the Oculomics Initiative website: https://commonfund. nih. gov/venture/oculomics .
Materials from the Webinar will be made available on that website for those unable to attend. The Common Fund may allocate up to $4,800,000 per year total costs (direct + F&A) for up to three years for the Venture Program Oculomics Initiative. The award(s) are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Although three awards each at $1,600,000 TC/year are anticipated, how funds may be split between awards has not been predetermined and will depend on (1) the objectives proposed by the applicants and how well they fit within the goals of Oculomics, (2) the quality of the applications received, (3) availability of funds, and (4) programmatic priorities, but the total for all costs for all awards will be no more than $4,800,000 per year for up to three years.
Non-domestic (non-U.S.) Entities (Foreign applicants) are not eligible to apply. Non-domestic components of domestic organizations are not eligible. Foreign components, as defined in the NIH Grants Policy Statement , are allowed.
The following entities are eligible to apply: Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education: Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISIs) Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) Faith-based or Community-based Organizations For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments American Indian/Native American Tribal Governments (Federally Recognized) American Indian/Native American Tribal Governments (Other than Federally Recognized) Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Native American Tribal Organizations (other than Federally recognized tribal governments) Please direct all inquiries to: National Eye Institute (NEI) Telephone: (301) 529-7370 Other Transactions Program Official Office of Strategic Coordination (OSC) Division of Program Coordination, Planning, and Strategic Initiatives Office of the Director (OD), NIH Telephone: (301) 451-6519 Weekly TOC for this Announcement NIH...
Turning Discovery Into Health ®
According to the current listing, eligibility includes: Academic institutions, nonprofit organizations, and other entities with relevant expertise. Confirm the full requirements in the official notice before applying.
The current listing shows $4,800,000 per year total (up to 3 years). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Development and Application of Ophthalmic Imaging Technologies to Advance Our Understanding of Systemic Diseases (OT2) is funded by NIH Common Fund. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NOT-RM-26-004 asks the public for NIH-wide research challenges worth a 10-year, cross-institute program. There is no budget, no biosketch, no page limit, and no award. What there is: the five criteria every Common Fund investment has met since 2006, a new bullet about small-lab burden, and a fund whose FY 2026 request came in at $347.4 million — down 49.3 percent.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleAvoid common NIH grant proposal mistakes including vague specific aims, weak methodology, and poor budget justification that lead to rejection.
Read article